ClydeMichaelJonesMDMSc , FACP

Hematologic Oncology, Melanoma

The Jones Clinic, PC - C. Michael Jones, M.D

Overview of Dr. Jones

Dr. Clyde Jones is an oncologist in Memphis, TN and is affiliated with multiple hospitals in the area, including Baptist Memorial Hospital - Memphis, Baptist Memorial Hospital-Union County, Baptist Memorial Hospital-Tipton, Methodist Le Bonheur Germantown Hospital, Methodist Healthcare Memphis Hospitals, and Lt. Col. Luke Weathers, Jr. VA Medical Center. He received his medical degree from University of Alabama School of Medicine and has been in practice 47 years. Dr. Jones accepts several types of health insurance, listed below. He is one of 56 doctors at Baptist Memorial Hospital - Memphis and one of 31 doctors at Methodist Le Bonheur Germantown Hospital who specialize in Oncology. He has 8 publications and over 350 citings.

Office
1030 Jefferson Ave
Memphis VA
Memphis, TN 38104
Book by Phone+1(901) 883-7162

Fax+1 901-751-6170

Education & Training

London School of Economics and Political ScienceMS, Health Economics, Ms, 2012 - 2014
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1978 - 1978
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1977 - 1978
Johns Hopkins UniversityResidency, Internal Medicine, 1976 - 1977
University of Alabama Medical CenterResidency, Internal Medicine, 1974 - 1976
University of Alabama School of MedicineClass of 1974

Certifications & Licensure

MD State Medical License 1976 - 2026
GA State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
MS State Medical License 1998 - 2025
TN State Medical License 1995 - 2025
TX State Medical License 1983 - 2025
AL State Medical License 1975 - 2024
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 1998
Top MD Consumers Checkbook

Clinical Trials

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma Start of enrollment: 1996 Jul 01
Completed
Phase 2
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
Unknown status
Phase 4
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
Recruiting
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

255 citations
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Hedy L. Kindler, Nofisat Ismaila, Samuel G. Armato, Raphael Bueno, Mary Hesdorffer
Journal of Clinical Oncology. 2018-01-18
5 citations
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III ...
Nadia Harbeck, Pere Gascón, Clyde M Jones, Allen Nixon, Andriy Krendyukov
Future Oncology. 2017-04-28
14 citations
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer.
Dana Backlund Cardin, Ramya Thota, Laura W. Goff, Jordan Berlin, Clyde M. Jones
American Journal of Clinical Oncology. 2017-03-01

Professional Memberships

American College of Physicians - ACP
Fellow

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Tennessee Network 5
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Carelink Health Plans PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Humana/ChoiceCare+ Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment